Venturi Wealth Management LLC Grows Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Venturi Wealth Management LLC lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2,175.0% during the 4th quarter, HoldingsChannel reports. The firm owned 91 shares of the medical research company’s stock after acquiring an additional 87 shares during the period. Venturi Wealth Management LLC’s holdings in Bio-Rad Laboratories were worth $30,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Gladius Capital Management LP bought a new position in shares of Bio-Rad Laboratories during the third quarter valued at approximately $32,000. Asset Planning Inc bought a new position in Bio-Rad Laboratories during the 4th quarter valued at approximately $33,000. UMB Bank n.a. raised its position in shares of Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in Bio-Rad Laboratories in the 3rd quarter worth about $55,000. Finally, Quarry LP grew its position in Bio-Rad Laboratories by 38.1% during the 3rd quarter. Quarry LP now owns 297 shares of the medical research company’s stock valued at $99,000 after purchasing an additional 82 shares during the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Performance

NYSE:BIO opened at $277.81 on Wednesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock has a 50-day simple moving average of $330.43 and a two-hundred day simple moving average of $333.76. The firm has a market capitalization of $7.78 billion, a PE ratio of -4.27 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a 52-week low of $262.12 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analysts Forecast Growth

BIO has been the subject of a number of research analyst reports. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Wells Fargo & Company lowered their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Citigroup lifted their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Royal Bank of Canada restated an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories has an average rating of “Moderate Buy” and a consensus target price of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.